uniQure N.V. chief legal officer Potts sells $70k in shares

uniQure N.V. (NASDAQ:QURE) Chief Legal Officer Jeannette Potts sold 4,670 ordinary shares of the company on June 16, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $15.14, for a total transaction value of $70,703. The prices ranged from $15.00 to $15.22. The transaction occurred as the stock trades near its InvestingPro Fair Value, with seven analysts recently revising their earnings estimates upward for the upcoming period.

The sale was executed to cover estimated withholding taxes upon the vesting of restricted share units, pursuant to automatic sale instructions. Following the transaction, Potts directly owns 115,073 ordinary shares of uniQure N.V. Despite recent price volatility, with the stock down about 19% year-to-date, uniQure maintains strong liquidity with a current ratio of 12x. For deeper insights into insider trading patterns and additional financial metrics, consider subscribing to InvestingPro.

In other recent news, uniQure has made significant strides in its business operations and regulatory engagements. During its 2025 Annual General Meeting of Shareholders, uniQure announced the reappointment of key board members and the approval of executive compensation. An amendment to the company’s 2014 Share Incentive Plan was also approved, increasing the number of ordinary shares reserved for issuance. In a strategic move, uniQure appointed Kylie O’Keefe as Chief Customer and Strategy Officer to spearhead the commercialization strategy for AMT-130, an investigational gene therapy for Huntington’s disease.

Furthermore, uniQure has aligned with the U.S. Food and Drug Administration (FDA) on critical aspects of its Biologics License Application for AMT-130, expected to be submitted in early 2026. The FDA has affirmed its support for an accelerated approval pathway, which could lead to potential approval in the second half of 2026. Analysts from Stifel and H.C. Wainwright have reiterated their Buy ratings for uniQure, citing confidence in the company’s regulatory interactions and the pivotal role of AMT-130 in driving future value. uniQure plans to present three-year top-line data from AMT-130’s ongoing Phase 1/2 study in the third quarter of 2025, with a pre-BLA meeting with the FDA scheduled for later that year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.